Richard Winer
Psychiatry · Roswell, GANPI 1164567277
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $77,075 of the $103,372 with a category attached, or 74.6%. 48 manufacturers reported payments, led by Supernus Pharmaceuticals, Inc. at 54.3% of the total. Reporting peaked in 2023 at $29,579 and has fallen 98.0% since, to $594 in 2025. Among psychiatry clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 454 payments — averaging $227.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Supernus Pharmaceuticals, Inc.$56K
- Ironshore Pharmaceuticals Inc.$16K
- Idorsia Pharmaceuticals US Inc$8K
- Shire North American Group Inc$8K
- Johnson & Johnson$7K
- Tris Pharma Inc$4K
- plus $5K from 42 others
What the payments were for
- Consulting fees$5,0705%
- Speaking & faculty fees$77,07575%
- Travel & lodging$12,97913%
- Food & beverage$8,2168%
- Education$320%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- QELBREE$54,379
- Jornay PM 20mg capsules (Bottle of 100)$14,898
- QUVIVIQ$7,905
- MYDAYIS$6,993
- SPRAVATO$6,286
- Dyanavel XR$3,796
- Quillichew ER$3,688
- Quillivant$3,688
- VYVANSE$320
- Auvelity$111
How this compares
$103,372 in reported general payments places this provider in the 95th percentile of 900 psychiatry providers in Georgia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyvanseLisdexamfetamine Dimesylate | 119 | $67,571 |
| Lisdexamfetamine Dimesylate | 24 | $7,182 |
| FetzimaLevomilnacipran Hcl | 11 | $6,287 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 91 | $2,935 |
| Clozapine | 12 | $2,338 |
| Alprazolam | 209 | $1,757 |
| Bupropion XlBupropion Hcl | 118 | $1,734 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 40 | $1,732 |
| Clonazepam | 189 | $1,452 |
| Escitalopram Oxalate | 97 | $1,193 |
| Trazodone Hcl | 76 | $903 |
| Quetiapine Fumarate | 65 | $846 |
| Chlorpromazine Hcl | 13 | $798 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 32 | $787 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 16 | $587 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse | $489 | $67,571119 claims |
| AbbVieFetzima | $839 | $6,28711 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 900 psychiatry providers in Georgia.
Other psychiatry in Roswell
- Michael RosenRoswell$141K
- Joel KirsonRoswell$99K
- Alexandra DoddRoswell$54K
- Scot BayRoswell$26K
- Richard PettyLoganville$2.9M
- Ann GrooverCalhoun$1.4M
- Todd AntinDecatur$1M
- Michael BanovMarietta$733K
- Ben HunterBrookhaven$499K
- Joel MorganValdosta$337K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.